CTC 96

CTC 96 is an antiviral agent, showing inhibitory effects particularly on herpes viruses and adenoviruses. CTC 96 directly blocks the fusion process between the viral envelope and the cell membrane, preventing the entry of viral nucleic acids and proteins into the cells. CTC 96 can completely block the penetration and intercellular transmission of HSV-1, preventing the synthesis of viral proteins and mRNA. CTC 96 exhibits significant anti-adenovirus activity in rabbit eye models. CTC 96 is also effective against varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV). CTC 96 can be used for broad-spectrum antiviral research^[1][2]. In Vitro:CTC 96 (0-50 μg/mL, 1 h) effectively inhibits HSV-1, Varicella-zoster virus (VZV) and vesicular stomatitis virus (VSV) infection in Vero cells^[1].
CTC 96 (50 μg/mL, 1 h) specifically blocks the membrane fusion step during which the virus enters the cell and does not interfere with the attachment of HSV-1 virus particles to the surface of Vero cells^[1].
CTC 96 (50 μg/mL) effectively blocks the entry of the virus, completely interrupting the release of the viral genome and the subsequent viral gene expression process in Vero cells^[1].
CTC 96 (50 μg/mL, 16 h) effectively inhibits the direct transmission of the virus among the already infected Vero cells^[1].
CTC-96 (0-250 μg/mL, 1 h) demonstrates virucidal activity against Ad5 in tissue culture with HeLa, A549 and SIRC cell lines^[2].
In Vivo:CTC 96 (25-50 μg/mL, eye drops, 6-9 time daily for 13-21 days) significantly alleviates the clinical symptoms of conjunctivitis in the rabbit eye adenovirus-induced corneal and conjunctival inflammation model^[2].